The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer

• Published in: Gynecologic oncology Vol. 153; no. 3; pp. 562 - 567
• Main Authors: van Baal, J.O.A.M., Van de Vijver, K.K., Algera, M.D., van der Aa, M.A., Sonke, G.S., van Driel, W.J., Kenter, G.G., Amant, F.C., Lok, C.A.R.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2019
• Subjects: Adjuvant chemotherapy; Early stage ovarian cancer; High-grade serous ovarian cancer; Staging; Adjuvant chemotherapy; Early stage ovarian cancer; Staging; High-grade serous ovarian cancer
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1016/j.ygyno.2019.03.257

The benefit of adjuvant chemotherapy for FIGO stage I, high-grade serous ovarian cancer (HGSOC) after optimal staging is a matter of debate. We investigated the effect of adjuvant chemotherapy on recurrence-free survival (RFS) and overall survival (OS) in a population-based cohort study. All patients diagnosed in the Netherlands between 2002 and 2014 with FIGO stage I HGSOC who underwent surgical staging were included. Data on clinical characteristics, histopathology, completeness of staging and survival were collected from the Netherlands Cancer Registry and Dutch Pathology Registry. Recurrence data was collected from hospital files. We used Kaplan-Meier methods to estimate RFS and OS and Cox-proportional hazard analyses to control for differences in baseline characteristics between patients who did or did not receive chemotherapy. We identified 223 patients who underwent optimal staging procedures including lymph node sampling. Events of disease recurrence occurred in 21 of the 101 patients (21%) who received adjuvant chemotherapy and in 46 of the 122 patients (38%) who did not (multivariable hazard ratio (HR), 0.37; 95%CI 0.22–0.64; p < 0.01). Five-year RFS was 81% after staging plus chemotherapy and 59% after staging only. At a median follow-up of 105 months, 21 patients (21%) in the chemotherapy group and 38 patients (31%) in the no-chemotherapy group had died (multivariable HR 0.50; 95%CI 0.28–0.89; p = 0.02). Ten-year OS was 78% with chemotherapy and 62% without chemotherapy. Adjuvant chemotherapy improves long-term RFS and OS in patients with FIGO stage I HGSOC after optimal staging. •Until now, no consensus has been reached on the benefit of adjuvant chemotherapy for early stage HGSOC.•After optimal staging and FIGO stage I HGSOC, adjuvant chemotherapy favors long-term RFS and OS.•Chemotherapy should be considered after optimal staging for FIGO stage I HGSOC to improve RFS and OS.